Company Description
Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells.
It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment of metastatic melanoma; C-145-04, of its product candidate lifileucel for recurrent, metastatic, or persistent cervical cancer; and C-145-03, of its product candidate LN-145, for recurrent and/or metastatic head and neck squamous cell carcinoma.
Iovance Biotherapeutics, Inc. has collaborations and licensing agreements with H.
Lee Moffitt Cancer Center; M.D. Anderson Cancer Center; Ohio State University; Centre hospitalier de l'Université de Montreal; Cellectis S.A.; and Novartis Pharma AG.
The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017.
Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.
| Country | United States |
| IPO Date | Oct 15, 2010 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 557 |
| CEO | Dr. Frederick G. Vogt Esq., J.D., Ph.D. |
Contact Details
Address: 825 Industrial Road San Carlos, California United States | |
| Website | https://www.iovance.com |
Stock Details
| Ticker Symbol | IOVA |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001425205 |
| CUSIP Number | 462260100 |
| ISIN Number | US4622601007 |
| Employer ID | 75-3254381 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Frederick G. Vogt Esq., J.D., Ph.D. | Interim Chief Executive Officer, President, General Counsel, Corporate Secretary & Director |
| Dr. Igor P. Bilinsky Ph.D. | Chief Operating Officer |
| Jean-Marc Bellemin M.B.A. | Chief Financial Officer, Principal Accounting Officer & Treasurer |
| Brian Shew M.B.A. | Senior Vice President & Head of Digital and Information Technology |
| Dr. Friedrich Graf Finckenstein M.D. | Chief Medical Officer |
| Dr. Raj K. Puri M.D., Ph.D. | Chief Regulatory Officer |
| Howard B. Johnson M.B.A. | Chief Business Officer |
| Kevin Smyth | Executive Vice President of Quality |
| Sara Pellegrino | Vice President of Investor Relations & Public Relations |
| Tracy Winton | Executive Vice President of Human Resources |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 04, 2024 | 4 | Filing |
| Dec 04, 2024 | 4 | Filing |
| Dec 04, 2024 | 4 | Filing |
| Dec 02, 2024 | 3 | Filing |
| Nov 21, 2024 | 8-K | Current Report |
| Nov 14, 2024 | 4 | Filing |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 08, 2024 | 8-K | Current Report |
| Nov 07, 2024 | 10-Q | Quarterly Report |
| Nov 07, 2024 | 8-K | Current Report |